Jonathan Young's most recent trade in Akero Therapeutics Inc was a trade of 890 Common Stock done at an average price of $23.9 . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 23.87 per share. | 30 Jun 2025 | 890 | 197,484 (0%) | 0% | 23.9 | 21,243 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 54.84 per share. | 18 Jun 2025 | 1,453 | 196,594 (0%) | 0% | 54.8 | 79,683 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 53.99 per share. | 10 Jun 2025 | 2,493 | 198,047 (0%) | 0% | 54.0 | 134,605 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 44.88 per share. | 12 Mar 2025 | 607 | 200,540 (0%) | 0% | 44.9 | 27,242 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 45.07 per share. | 04 Mar 2025 | 38,553 | 201,147 (0%) | 0% | 45.1 | 1,737,622 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 44.17 per share. | 04 Mar 2025 | 11,447 | 239,700 (0%) | 0% | 44.2 | 505,591 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 53.57 per share. | 03 Feb 2025 | 5,100 | 256,047 (0%) | 0% | 53.6 | 273,182 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 54.06 per share. | 03 Feb 2025 | 4,900 | 251,147 (0%) | 0% | 54.1 | 264,879 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2025 | 43,064 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.36 per share. | 24 Jan 2025 | 43,064 | 261,147 (0%) | 0% | 6.4 | 274,059 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.03 per share. | 02 Jan 2025 | 10,000 | 218,083 (0%) | 0% | 28.0 | 280,330 | Common Stock |
| Akero Therapeutics Inc | Young Jonathan | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 73,700 | 73,700 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 24,300 | 228,083 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Young Jonathan | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 30.79 per share. | 10 Dec 2024 | 2,503 | 203,783 (0%) | 0% | 30.8 | 77,067 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 32.13 per share. | 02 Dec 2024 | 10,000 | 206,286 (0%) | 0% | 32.1 | 321,310 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.09 per share. | 01 Nov 2024 | 40,716 | 267,002 (0%) | 0% | 21.1 | 858,700 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 40,716 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 31.25 per share. | 01 Nov 2024 | 34,943 | 232,059 (0%) | 0% | 31.3 | 1,092,109 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 32.27 per share. | 01 Nov 2024 | 15,481 | 216,578 (0%) | 0% | 32.3 | 499,525 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 32.94 per share. | 01 Nov 2024 | 292 | 216,286 (0%) | 0% | 32.9 | 9,618 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 30.15 per share. | 14 Oct 2024 | 40,000 | 226,286 (0%) | 0% | 30.2 | 1,206,080 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 40,000 | 40,716 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.09 per share. | 14 Oct 2024 | 40,000 | 266,286 (0%) | 0% | 21.1 | 843,600 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.18 per share. | 01 Oct 2024 | 10,000 | 226,286 (0%) | 0% | 28.2 | 281,770 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 26.18 per share. | 13 Sep 2024 | 568 | 236,286 (0%) | 0% | 26.2 | 14,870 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 26.42 per share. | 03 Sep 2024 | 3,710 | 238,144 (0%) | 0% | 26.4 | 98,014 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 27.58 per share. | 03 Sep 2024 | 1,290 | 236,854 (0%) | 0% | 27.6 | 35,573 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 26.44 per share. | 01 Aug 2024 | 3,031 | 243,823 (0%) | 0% | 26.4 | 80,140 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 27.23 per share. | 01 Aug 2024 | 1,969 | 241,854 (0%) | 0% | 27.2 | 53,616 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 23.40 per share. | 28 Jun 2024 | 5,000 | 246,854 (0%) | 0% | 23.4 | 117,020 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 19.94 per share. | 28 Jun 2024 | 1,064 | 251,854 (0%) | 0% | 19.9 | 21,217 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 22.64 per share. | 11 Jun 2024 | 2,516 | 250,790 (0%) | 0% | 22.6 | 56,965 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 19.29 per share. | 03 Jun 2024 | 5,000 | 253,306 (0%) | 0% | 19.3 | 96,440 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 20.15 per share. | 01 May 2024 | 5,000 | 258,306 (0%) | 0% | 20.2 | 100,750 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 24.33 per share. | 01 Apr 2024 | 4,600 | 263,706 (0%) | 0% | 24.3 | 111,903 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 25.02 per share. | 01 Apr 2024 | 400 | 263,306 (0%) | 0% | 25.0 | 10,010 | Common Stoek |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.33 per share. | 13 Mar 2024 | 651 | 268,306 (0%) | 0% | 28.3 | 18,443 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 83,321 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.61 per share. | 01 Mar 2024 | 83,321 | 268,957 (0%) | 0% | 0.6 | 51,242 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.36 per share. | 27 Dec 2023 | 5,414 | 190,545 (0%) | 0% | 6.4 | 34,433 | Common Stock |
| Akero Therapeutics Inc | Young Jonathan | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 5,414 | 43,064 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 24.00 per share. | 27 Dec 2023 | 5,414 | 185,131 (0%) | 0% | 24 | 129,936 | Common Stock |
| Akero Therapeutics Inc | Young Jonathan | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 20.76 per share. | 14 Dec 2023 | 543 | 185,131 (0%) | 0% | 20.8 | 11,273 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 146,237 | 146,237 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Young Jonathan | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 32,497 | 185,674 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 55.16 per share. | 13 Jun 2023 | 538 | 183,739 (0%) | 0% | 55.2 | 29,676 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.47 per share. | 10 Mar 2023 | 634 | 184,277 (0%) | 0% | 43.5 | 27,560 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 03 Jan 2023 | 8,777 | 193,688 (0%) | 0% | 0.6 | 5,398 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 8,777 | 83,321 | - | - | Employee Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 54.64 per share. | 03 Jan 2023 | 8,777 | 184,911 (0%) | 0% | 54.6 | 479,560 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 49.57 per share. | 27 Dec 2022 | 12,500 | 182,449 (0%) | 0% | 49.6 | 619,609 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2022 | 11,778 | 48,478 | - | - | Employee Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.36 per share. | 27 Dec 2022 | 11,778 | 194,949 (0%) | 0% | 6.4 | 74,908 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2022 | 722 | 92,098 | - | - | Employee Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.61 per share. | 27 Dec 2022 | 722 | 183,171 (0%) | 0% | 0.6 | 444 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 29,073 | 87,221 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 86,379 | 86,379 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 19,195 | 182,449 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2022 | 12,500 | 60,256 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.36 per share. | 25 Oct 2022 | 12,500 | 175,754 (0%) | 0% | 6.4 | 79,500 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 44.72 per share. | 25 Oct 2022 | 12,500 | 163,254 (0%) | 0% | 44.7 | 558,944 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2022 | 29,074 | 29,074 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2022 | 29,074 | 58,148 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 07 Jan 2022 | 27,744 | 163,254 (0%) | 0% | 0.6 | 17,063 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2022 | 26,296 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2022 | 1,448 | 92,820 | - | - | Employee Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2021 | 87,221 | 87,221 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 24.27 per share. | 03 Nov 2021 | 18,780 | 141,730 (0%) | 0% | 24.3 | 455,791 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 24.33 per share. | 03 Nov 2021 | 6,220 | 135,510 (0%) | 0% | 24.3 | 151,333 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 24.04 per share. | 01 Sep 2021 | 12,500 | 160,510 (0%) | 0% | 24.0 | 300,500 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 15 Jul 2021 | 9,000 | 173,010 (0%) | 0% | 0.6 | 5,535 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 9,000 | 26,296 | - | - | Employee Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 26.24 per share. | 01 Jun 2021 | 3,055 | 164,010 (0%) | 0% | 26.2 | 80,151 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 30.56 per share. | 03 May 2021 | 3,055 | 167,065 (0%) | 0% | 30.6 | 93,361 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.75 per share. | 01 Apr 2021 | 3,055 | 170,120 (0%) | 0% | 28.7 | 87,828 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 01 Mar 2021 | 2,855 | 173,375 (0%) | 0% | 30.4 | 86,878 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 31.17 per share. | 01 Mar 2021 | 200 | 173,175 (0%) | 0% | 31.2 | 6,234 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 29.19 per share. | 01 Feb 2021 | 2,855 | 176,430 (0%) | 0% | 29.2 | 83,337 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 29.92 per share. | 01 Feb 2021 | 200 | 176,230 (0%) | 0% | 29.9 | 5,984 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.12 per share. | 07 Jan 2021 | 10,000 | 179,285 (0%) | 0% | 28.1 | 281,200 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2021 | 7,500 | 35,296 | - | - | Employee Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.62 per share. | 07 Jan 2021 | 7,500 | 189,285 (0%) | 0% | 0.6 | 4,613 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 25.27 per share. | 04 Jan 2021 | 2,960 | 181,885 (0%) | 0% | 25.3 | 74,799 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 26.00 per share. | 04 Jan 2021 | 100 | 181,785 (0%) | 0% | 26 | 2,600 | Common Stock |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2020 | 77,580 | 77,580 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Jonathan Young | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 17.07 per share. | 08 Dec 2020 | 1,245 | 184,845 (0%) | 0% | 17.1 | 21,250 | Common Stock |